UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030909
Receipt number R000035291
Scientific Title Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study)
Date of disclosure of the study information 2018/01/20
Last modified on 2018/01/20 15:13:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study)

Acronym

NSOX study

Scientific Title

Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study)

Scientific Title:Acronym

NSOX study

Region

Japan


Condition

Condition

gastric cancer with peritoneal metastasis

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Phase 1: To determine the maxim um-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs) of NSOX regimen
Phase 2: To examine the efficacy and safety in the recommended dose

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I,II


Assessment

Primary outcomes

Phase I: DLT
Phase II: The rate of negative conversion in P1

Key secondary outcomes

Phase 1: MTD, RD, adverse events, pharmacokinetics
Phase 2: completion rate of treatment, response rate, curative resection rate, postoperative complication, pathological response rate, progression free survival, duration of disease control, recurrent free survival after gastrectomy, overall survival, time to treatment failure


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

nab-paclitaxel,S-1, oxaliplatin

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Histologically proven adenocarcinoma of gastric cancer and positive peritoneal dissemination by staging laparoscopy
2. HER2 negative (or untested)
3. No non-curable factors except peritoneal dissemination
4. No prior chemotherapy or radiation therapy (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >6 months for S-1 therapy)
5. age 20<= years, 75>= years
6. ECOG PS 0 or 1
7. Ingestible
8. Hematological status: neutrophils (ANC)>=1,500 /mm3; platelets >=100,000 /mm3; haemoglobin >=8g/dL, Adequate renal function: serum creatinine level <=1.2mg/dl,Ccr >=60mL/min, Adequate liver function: serum bilirubin <=2.0 xupper normal limit (ULN), AST/ALT<=100 U/L
9. Expected life span >=3 months
10.Signed and dated informed consent

Key exclusion criteria

1. History of hypersensitivity to nab-paclitaxel, S-1, oxaliplatin
2. Contraindication to nab-paclitaxel, S-1, oxaliplatin
3. Infectious disease
4. HBs-antigen positive
5. Severe complication
6. Neuropathy with symptoms
7. Brain metastasis with clinical symptoms
8. Watery diarrhea.
9. Active double cancer
10. Persons to be pregnant or to make pregnant
11. Any subject judged by the investigator to be unfit for any reason to participate in the study

Target sample size

35


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masaki Nakamura

Organization

Wakayama Medical University, School of Medicine

Division name

Second Department of Surgery

Zip code


Address

811-1 Kimiidera, Wakayama city, Wakayama, Japan

TEL

073-441-0613

Email

twins@wakayama-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masaki Nakamura

Organization

Wakayama Medical University, School of Medicine

Division name

Second Department of Surgery

Zip code


Address

811-1 Kimiidera, Wakayama city, Wakayama, Japan

TEL

073-441-0613

Homepage URL


Email

twins@wakayama-med.ac.jp


Sponsor or person

Institute

Wakayama Medical University, School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Wakayama Medical University, School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

和歌山県立医科大学附属病院


Other administrative information

Date of disclosure of the study information

2018 Year 01 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 01 Month 11 Day

Date of IRB


Anticipated trial start date

2018 Year 01 Month 12 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 01 Month 20 Day

Last modified on

2018 Year 01 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035291


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name